Sage Therapeutics (NASDAQ:SAGE) Raised to “Hold” at StockNews.com

Sage Therapeutics (NASDAQ:SAGE) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other research firms also recently commented on SAGE. TD Cowen decreased their target price on shares of Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, April 18th. The Goldman Sachs Group decreased their target price on shares of Sage Therapeutics from $28.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday. Morgan Stanley upped their price objective on shares of Sage Therapeutics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. Mizuho reduced their price objective on shares of Sage Therapeutics from $20.00 to $18.00 and set a “neutral” rating for the company in a research report on Friday. Finally, JPMorgan Chase & Co. upped their price objective on shares of Sage Therapeutics from $24.00 to $29.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 26th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $37.72.

Sage Therapeutics Trading Up 0.8 %

Shares of NASDAQ SAGE opened at $13.69 on Friday. The firm’s 50-day moving average price is $18.56 and its 200-day moving average price is $20.64. Sage Therapeutics has a 1-year low of $10.92 and a 1-year high of $59.99. The firm has a market capitalization of $822.91 million, a P/E ratio of -1.51 and a beta of 0.86.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.63) by ($0.17). The business had revenue of $7.90 million for the quarter, compared to the consensus estimate of $5.26 million. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The company’s revenue was up 139.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.46) earnings per share. Equities research analysts forecast that Sage Therapeutics will post -6.3 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SAGE. CWM LLC boosted its stake in Sage Therapeutics by 274.2% in the third quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 883 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Sage Therapeutics by 95.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 748 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Sage Therapeutics by 17.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,289 shares of the biopharmaceutical company’s stock valued at $191,000 after buying an additional 1,375 shares in the last quarter. Values First Advisors Inc. purchased a new stake in shares of Sage Therapeutics during the 3rd quarter valued at approximately $219,000. Finally, Quest Partners LLC purchased a new stake in shares of Sage Therapeutics during the 4th quarter valued at approximately $261,000. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.